Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer--Letter

Clin Cancer Res. 2016 Apr 1;22(7):1827. doi: 10.1158/1078-0432.CCR-15-2824.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Cetuximab*
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms / drug therapy*
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Protein Kinase Inhibitors
  • ErbB Receptors
  • Cetuximab